Frailty Predicts Survival in Older Blood Cancer Patients
A Dana-Farber study of more than 1,000 older adults links frailty measures to survival in blood cancers.
Updated on Nov. 10, 2026 in Diseases

Researchers at Dana-Farber Cancer Institute found that frailty predicts survival among older adults with blood cancers. The study, published in Haematologica, analyzed more than 1,000 patients evaluated through the institution's Older Adult Hematologic Malignancies Program over 10 years.
Why it matters
Older adults are often underrepresented in clinical trials of new cancer therapies, so tools that identify frailty can help clinicians tailor care to individual patients. Frailty-guided care is already recommended in national oncology guidelines, and this study adds evidence supporting its use in blood cancers.
The analysis used three geriatric frailty tools across more than 1,000 patients with a median age of 78 and a median follow-up of 43 months. Whether these survival differences hold for patients treated outside a specialized geriatric oncology program is not addressed in the findings.
The players
Dana-Farber Cancer Institute
A Boston-based cancer center affiliated with Harvard Medical School that conducted the study through its Older Adult Hematologic Malignancies Program.
The details
The study drew on patients evaluated through Dana-Farber's Older Adult Hematologic Malignancies Program, which was launched in 2015 to bring geriatric assessment into routine cancer care. Researchers applied a cumulative deficit frailty index, a phenotypic frailty model and a four-meter walking-speed test, and found that frail and pre-frail patients had a significantly higher risk of death than robust patients across all three approaches.
Timeline
2015: Dana-Farber launches the Older Adult Hematologic Malignancies Program to bring geriatric assessment into cancer care.
Over 10 years: The program evaluates more than 1,000 older patients.
Median of 43 months: Median follow-up period for study survivors.
Health Landscape
The findings build on the frailty-guided care already recommended in national oncology guidelines, adding blood cancer survival data to an approach that has so far been applied mainly to other malignancies. Because older adults are underrepresented in trials of new therapies, this evidence bears on how real-world treatment decisions for aging patients are made.
Older patients with blood cancers may be assessed for frailty as part of their treatment planning, which could shape decisions about therapy intensity. Patients and caregivers can ask their care team whether a geriatric or frailty assessment is part of their evaluation.
The takeaway
Frailty screening can reveal risk that age alone does not, so older patients with blood cancers may benefit from asking whether a frailty assessment is part of their care plan. Discussing these measures with an oncologist can help align treatment with an individual's overall health.
Further reading
Explore more cancer coverage to see how older patient care is changing across the field.
Source note: This article includes information reported by OncLive.






